GAMMA Investing
BLTE icon

GAMMA Investing’s Belite Bio BLTE Stock Holding History

GAMMA Investing’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$301K Buy
1,771
+85
+5% +$13.8K 0.01% 1034
2026
Q2 		$260K Sell
1,686
-21
-1% -$3.22K 0.01% 1075
2026
Q1 		$272K Sell
1,707
-72
-4% -$12.1K 0.01% 909
2025
Q4 		$285K Buy
1,779
+21
+1% +$2.49K 0.01% 799
2025
Q3 		$130K Buy
1,758
+176
+11% +$11.6K 0.01% 1285
2025
Q2 		$91.3K Sell
1,582
-267
-14% -$16.3K 0.01% 1519
2025
Q1 		$122K Buy
1,849
+559
+43% +$33.7K 0.01% 1089
2024
Q4 		$81.4K Buy
1,290
+419
+48% +$27.6K 0.01% 1267
2024
Q3 		$40.8K Buy
871
+443
+104% +$21.5K ﹤0.01% 1639
2024
Q2 		$19.6K Buy
428
+194
+83% +$8.4K ﹤0.01% 1878
2024
Q1 		$8.98K Buy
234
+35
+18% +$1.57K ﹤0.01% 2123
2023
Q4 		$8.64K Buy
+199
New +$7.65K ﹤0.01% 1985

Other funds holding BLTE

Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $148B AUM 31.56% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Patient Square Capital
Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
NM
NWI Management New York $2.67B AUM 61.94% 1-Year Est. Return

GAMMA Investing's BLTE Position: Q3 2026 in Review

GAMMA Investing increased its Belite Bio (BLTE) stake by 5% in Q3 2026, buying an estimated $13.8K and bringing the position to 1,771 shares worth $301K. The position accounts for 0.01% of the portfolio, ranked #1034.

GAMMA Investing first reported a position in BLTE in Q4 2023 and has held it in 12 quarters since. 54 funds tracked by Wall St. Rank hold BLTE as of Q3 2026.

  • GAMMA Investing held 1,771 shares of Belite Bio worth $301K as of Q3 2026.
  • GAMMA Investing bought 85 Belite Bio shares in Q3 2026, an estimated $13.8K.
  • Belite Bio made up 0.01% of GAMMA Investing's portfolio in Q3 2026, its #1034 holding.
  • GAMMA Investing first reported a position in Belite Bio in Q4 2023 and has held it in 12 quarters since.
  • 54 funds tracked by Wall St. Rank held Belite Bio as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.